Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2009 | 06-2009 | 03-2009 | 12-2008 | 09-2008 | |
| Sales | 11,290,000 | 10,742,000 | 9,926,000 | 10,348,000 | 11,030,000 |
| Cost of Goods | 3,103,000 | 2,824,000 | 2,585,000 | 2,834,000 | 3,021,000 |
| Gross Profit | 8,187,000 | 7,918,000 | 7,341,000 | 7,514,000 | 8,009,000 |
| Operating Expenses | 5,553,000 | 5,554,000 | 4,994,000 | 5,834,000 | 5,674,000 |
| Operating Income | 2,634,000 | 2,364,000 | 2,347,000 | 1,680,000 | 2,335,000 |
| Interest Expense | 173,000 | 136,000 | 86,000 | 76,000 | 96,000 |
| Other Income | 30,000 | 215,000 | 35,000 | 155,000 | 181,000 |
| Pre-tax Income | 2,491,000 | 2,443,000 | 2,296,000 | 1,759,000 | 2,420,000 |
| Income Tax | 379,000 | 399,000 | 321,000 | 252,000 | 338,000 |
| Net Income Continuous | 2,112,000 | 2,044,000 | 1,975,000 | 1,507,000 | 2,082,000 |
| Net Income Discontinuous | N/A | N/A | N/A | 42,000 | 19,000 |
| Minority Interests | 14,000 | 9,000 | 13,000 | 10,000 | 11,000 |
| Net Income | $2,098,000 | $2,035,000 | $1,962,000 | $1,539,000 | $2,090,000 |
| EPS Basic Total Ops | 0.93 | 0.90 | 0.87 | 0.69 | 0.92 |
| EPS Basic Continuous Ops | 0.93 | 0.90 | 0.87 | 0.66 | 0.92 |
| EPS Diluted Total Ops | 0.92 | 0.89 | 0.86 | 0.67 | 0.92 |
| EPS Diluted Continuous Ops | 0.92 | 0.90 | 0.87 | 0.65 | 0.92 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | 0.02 | 0.00 |
| EBITDA(a) | $3,248,000 | $2,914,000 | $2,895,000 | $1,680,000 | $3,196,000 |